Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.5 (EPT/RI)-Alliance Pharma plc

13 Jan 2025 09:02

Form 8.5 (EPT/RI)-Alliance Pharma plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeAlliance Pharma plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is financial advisor to Aegros Bidco Limited (a newly incorporated company indirectly owned by DBAY Affiliates and the ERES IV Fund)
(d) Date dealing undertaken:10th January 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A”N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
Ordinary sharesPurchases3,631,97261.260.8
Ordinary sharesSales3,679,32061.361

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
N/AN/AN/AN/AN/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
N/AN/AN/AN/AN/AN/AN/AN/A

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
N/AN/AN/AN/AN/A

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
N/AN/AN/AN/A

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure:13th January 2025
Contact name:Priyali Bhattacharjee
Telephone number:+91 9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
11th Mar 20253:10 pmRNSForm 8.3 - Alliance Pharma plc
11th Mar 202512:48 pmRNSForm 8.3 - Alliance Pharma plc
11th Mar 202512:17 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 10 03 2025] - (CGWL)
11th Mar 202510:02 amGNWForm 8.5 (EPT/RI)-Alliance Pharma plc
11th Mar 20259:47 amRNSForm 8.5 (EPT/RI) - Alliance Pharma plc
11th Mar 20257:00 amRNSForm 8.3 - Alliance Pharma plc
10th Mar 20253:00 pmBUSForm 8.3 - APH LN
10th Mar 20251:51 pmPRNForm 8.3 - Alliance Pharma Plc
10th Mar 202512:37 pmRNSForm 8.3 - Alliance Pharma PLC 10.03.2025
10th Mar 20257:58 amGNWForm 8.5 (EPT/RI)-Alliance Pharma plc
10th Mar 20257:00 amRNSFinal Increased Recommended Cash Offer
7th Mar 20256:06 pmRNSNotification of Major Holdings
7th Mar 20253:00 pmBUSForm 8.3 - APH LN
7th Mar 20251:57 pmPRNForm 8.3 - Alliance Pharma Plc
7th Mar 202511:47 amRNSForm 8.3 - Alliance Pharma PLC 07.03.2025
7th Mar 20258:41 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
6th Mar 20253:30 pmRNSForm 8.3 - ALAPH LN
6th Mar 20253:06 pmRNSForm 8.3 - Alliance Pharma plc
6th Mar 20253:00 pmBUSForm 8.3 - APH LN
6th Mar 20251:41 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
6th Mar 20251:05 pmPRNForm 8.3 - Alliance Pharma Plc
6th Mar 202512:12 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 05 03 2025] - (CGWL)
6th Mar 202511:41 amRNSForm 8.3 - Alliance Pharma Plc
6th Mar 202511:28 amRNSForm 8.3 - Alliance Pharma PLC 06.03.2025
6th Mar 20258:27 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
5th Mar 20253:30 pmRNSForm 8.3 - APH LN
5th Mar 20253:13 pmRNSForm 8.3 - Alliance Pharma plc
5th Mar 20252:02 pmGNWForm 8.3 - [ALLIANCE PHARMA PLC - 04 03 2025] - (CGWL)
5th Mar 20251:42 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
5th Mar 202510:04 amRNSForm 8.3 - Alliance Pharma PLC 05.03.2025
5th Mar 20259:05 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
4th Mar 20253:30 pmRNSForm 8.3 - ALAPH LN
4th Mar 20253:00 pmBUSForm 8.3 - APH LN
4th Mar 20252:33 pmRNSForm 8.3 - ALLIANCE PHARMA PLC
4th Mar 202511:43 amPRNForm 8.3 - Alliance Pharma Plc
4th Mar 202510:33 amRNSForm 8.3 - Alliance Pharma PLC 04.03.2025
4th Mar 20259:24 amGNWForm 8.5 (EPT/RI) - Alliance Pharma plc
4th Mar 20258:29 amRNSForm 8.3 - Alliance Pharma plc
3rd Mar 20253:35 pmRNSNotification of Major Holdings
3rd Mar 20253:30 pmRNSForm 8.3 - ALAPH LN
3rd Mar 20253:00 pmBUSForm 8.3 - APH LN
3rd Mar 20252:15 pmPRNForm 8.3 - Alliance Pharma Plc
3rd Mar 20257:00 amRNSForm 8.3 - Alliance Pharma plc
28th Feb 20253:30 pmRNSForm 8.3 - ALAPH LN
28th Feb 20253:25 pmRNSForm 8.3 - Alliance Pharma plc
28th Feb 20253:00 pmBUSForm 8.3 - APH LN
28th Feb 20252:38 pmRNSForm 8.3 - Alliance Pharma PLC
28th Feb 20251:24 pmPRNForm 8.3 - Alliance Pharma Plc
28th Feb 20251:20 pmRNSConfirmation of Adjournment
28th Feb 202510:06 amRNSForm 8.3 - Alliance Pharma PLC 27.02.2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.